A neutralization enzyme immunoassay (N-EIA) was developed for the detection of antibody titer rises in sera of patients infected with influenza A (H3N2) virus. In this N-EIA, a selected strain of influenza A (H3N2) virus was added to monolayers of LLC-MK2 cells in microtiter plates. After 24 h, the replicated virus could be demonstrated with a virus-specific enzyme-labeled monoclonal antibody. Preincubation of the influenza virus with convalescent-phase sera of patients infected with influenza A (H3N2) virus resulted 1 day later in decreased absorbance values that could be used for calculation of neutralization titers. From use of paired serum samples from 10 patients with a history of flu-like symptoms, the results obtained with N-EIA correlated well (r = 0.83) with those of the standard hemagglutination inhibition test.
Hemagglutination inhibition (HAI) and complement fixation assays are the methods most commonly used for serodiagnosis of influenza virus infections. Neutralization tests, however, have been reported to be more specific and more sensitive (1, (3) (4) (5) (13) (14) (15) . The classical neutralization methods based on plaque reduction or hemadsorption inhibition are laborious and take several days to complete. Therefore, they are less suitable for screening large numbers of serum samples. Recently, we have developed neutralization tests based on an enzyme immunoassay for mumps virus, encephalomyocarditis virus, and Semliki Forest virus in cell culture with horseradish peroxidase (HRPO)-labeled virus-specific monoclonal antibodies (MAbs), which can be applied for rapid and objective titration of virus infectivity and virus-neutralizing antibodies (8, (16) (17) (18) .
In the present paper, we describe such an assay for the assessment of neutralizing activities of human serum samples against influenza A (H3N2) virus. MATERIALS (7) with slight modifications as described elsewhere (2) . To prevent nonspecific inhibition, human sera were pretreated with in-house-prepared receptor-destroying enzyme.
Detection of viral antigen on infected cells by direct ETA. Influenza virus was added together with 1.5 x 105 LLC cells, resulting in a multiplicity of infection (MOI) of 0.1, to 96-well flat-bottom microtiter plates (Nunc, Roskilde, Denmark) and incubated at 37°C. Wells containing grown monolayers were fixed at selected time intervals with 0.05 ml of 0.15% glutaraldehyde (Merck, Darmstadt, Germany) per well. After 32 h of incubation, all monolayers had been fixed. Subsequently, the plates were washed with tap water and incubated with HRPOlabeled MAb UM 11-52 for 1 h at 37°C. The plates were washed again with tap water, and bound peroxidase was visualized by incubation with 0.05 ml of substrate solution per well (TMB and H202 in 0.11 M sodium acetate buffer, pH 5.5). After 20 min of incubation at room temperature, the enzyme reaction was stopped with 0.1 ml of 0.18 N H2SO4 per well and the reaction was quantified by measuring the A450 with a Titertek Multiskan spectrophotometer (Flow Laboratories).
N-EIA. For the assessment of the influenza virus-neutralizing activities of patient serum samples, the preparations, which had been heat inactivated at 56°C for 30 min, were serially diluted in twofold steps in DMEM supplemented with 2% FCS in 96-well microtiter plates at volumes of 0.025 ml per well. Then, 0.025 ml of influenza A virus in DMEM containing 2% FCS was added to each well and the plates were incubated for 1 h at 37°C. Subsequently, from each mixture three aliquots of 0.01 ml were transferred to three wells of other 96-well microtiter plates and 1.5 x 104 LLC cells in DMEM containing 2% FCS were added. The plates were incubated at 37°C for 22 h, fixed with 0.05 ml of 0.15% glutaraldehyde per well, and washed with tap water. Finally, a direct EIA was performed as described above, using HRPO-labeled MAb UM 11-52. Virus controls (virus and cells only) and cell controls were each determined in fourfold in every microtiter plate.
For the calculation of the MOI used in N-EIA, the number of PFU of influenza strain A/Delft/2696/90 virus was assessed by using an immunoplaque assay slightly modified from that described by Harder et al. (6) . The number of PFU was determined as 8. 1990 and showing a rise in HAI titer against influenza A/Delft/2696/90 (H3N2) virus were tested by the newly developed N-EIA. The resulting neutralizing antibody titers at 50% A450 reduction corresponded well with the HAI titers ( Table   1 ). The overall correlation coefficient was 0.83. With eight patients, the antibody titers in the acute-phase serum samples were below the detection level (a titer of 6) when determined in HAI tests. When N-EIA was used, however, neutralizing activity could be demonstrated in all acute-phase serum samples. Figure 3 illustrates the method by displaying the curves for three paired serum samples with undetectable, low, and high rises in antibody titer.
DISCUSSION
The multiplication of influenza virus could be monitored by EIA (Fig. 1) . Our results correspond very well with those found by Watanabe and Mackenzie (19) . A rise in absorbance value could be prevented or diminished by preincubation of the virus inoculum with neutralizing antibody (N-EIA). This technique enabled titration of the neutralizing activities of human serum samples within 24 h (Table 1 and Fig. 3 ). Similar results were obtained when neutralizing activities of MAbs directed against influenza A (H3N2) virus were assessed (data not shown). Furthermore, it would be interesting to compare N-EIA with HAI for characterization of panels of MAbs directed against influenza viruses (unpublished data).
To become infective, the hemagglutinin (HA) of newly synthesized influenza virus has to be cleaved proteolytically into the subunits HAl and HA2 (11) . In vitro, this can be achieved by addition of trypsin (10) . In our assay, this effect of trypsin is reflected by the divergence of the rise in absorbance values that resulted in different levels of the asymptote, as measured on virus-infected cells with and without the presence of the enzyme (Fig. 1) . This assay may therefore be used to assess the effect of other proteolytic enzymes on influenza virus multiplication.
Because in the N-EIA only one cycle of multiplication of influenza virus is needed, addition of trypsin is not essential.
The choice of a suitable endpoint reading can be a problem in the N-EIA. The virus titration curve (Fig. 2) shows that every 50% reduction of the virus concentration yields a percentage of reduction of the absorbance value which depends on the virus input. This necessitates the prior construction of a titration curve to establish the optimal virus dose. (Table 1) . According to the prevailing theory that one antibody molecule might neutralize one virus particle (single hit), higher titers would be expected in N-EIA than in HAI. Actually, about 70 antibody molecules are necessary to neutralize one influenza virus particle (14) . This could explain why antibody titers measured in convalescent-phase serum samples by N-EIA are of the same order of magnitude as those measured by HAI. A close correlation between HAI and neutralization titers in serum samples of volunteers after vaccination when tested against the vaccine strain has also been demonstrated by Okuno et al. (13) .
The nature of the neutralizing activities measured in acutephase serum samples that were determined as negative by HAI assay is not known. They could be due to a sensitivity of the N-EIA higher than that of the HAI or, alternatively, to non-immune factors that are present in some human serum samples and that become inactive when treated with receptordestroying enzyme as is done in the HAI test.
A disadvantage of the N-EIA is the need for the development of suitable MAbs. Especially with the highly variable influenza virus (2), there is a considerable risk that previously suitable MAbs do not react with newly appearing variants of the virus.
Determination of neutralizing antibody titers may have special relevance in relation to the assessment of the immune response after influenza vaccination because it is not certain that all HAI antibodies can also accomplish neutralization. The N-EIA is suitable for the accurate titration of neutralizing antibodies in a large number of serum samples using small amounts of serum, as has been demonstrated in a recent study on the immune status of children after mumps vaccination (8) .
